ATHE
Alterity Therapeutics Ltd - ADR

8,956
Loading...
Loading...
News
all
press releases
Alterity Therapeutics Stock Doubles Premarket On Positive MSA Trial Results: Retail Excitement Soars
A 50mg dose of its ATH434 showed 8% reduction in clinical progression of early-stage multiple system atrophy vs. placebo.
Stocktwits·8mo ago
News Placeholder
More News
News Placeholder
Alterity Therapeutics Unveils Annual Financial Results
Alterity Therapeutics Ltd. (AU:ATH) has released an update. Alterity Therapeutics Limited has released its Preliminary Final Report for the year en...
TipRanks Financial Blog·1y ago
News Placeholder
Alterity Therapeutics Halts Trading for Clinical Update
Alterity Therapeutics Ltd. (AU:ATH) has released an update. Alterity Therapeutics Limited (ATH) has requested a trading halt pending an announcemen...
TipRanks Financial Blog·1y ago
News Placeholder
Alterity Therapeutics receives A$3.9M R&D Tax Incentive refund
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·1y ago
News Placeholder
Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund
MELBOURNE, AustraliaandSAN FRANCISCO, March 27, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ( Alterity or the Company ), a biotechnology company...
Globe Newswire·1y ago
News Placeholder
Short Interest in Alterity Therapeutics Limited (NASDAQ:ATHE) Grows By 25.6%
Alterity Therapeutics Limited (NASDAQ:ATHE Get Free Report) saw a large increase in short interest in the month of February. As of February 15th, there was short interest totalling 37,800...
Zolmax·2y ago
News Placeholder
Alterity Therapeutics Ltd (ADR) trading halted, news pending
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·2y ago
News Placeholder
Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting
Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's Disease to be Presented at International Conference Baseline Biomarker Data to be Presented from Ongoing ATH434-201 Phase 2...
Globe Newswire·2y ago
News Placeholder
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review
- ATH434-201 Trial on Track to Complete in November 2024 - Top-Line Data Expected in January 2025 - MELBOURNE, AUSTRALIA AND SAN FRANCISCO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Alterity...
Globe Newswire·2y ago
News Placeholder
Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week
MELBOURNE, Australia and SAN FRANCISCO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ( Alterity or the Company ), a biotechnology company dedicated to...
Globe Newswire·2y ago

Latest ATHE News

View

Advertisement. Remove ads.

Advertisement. Remove ads.